JP2020506169A5 - - Google Patents

Download PDF

Info

Publication number
JP2020506169A5
JP2020506169A5 JP2019537351A JP2019537351A JP2020506169A5 JP 2020506169 A5 JP2020506169 A5 JP 2020506169A5 JP 2019537351 A JP2019537351 A JP 2019537351A JP 2019537351 A JP2019537351 A JP 2019537351A JP 2020506169 A5 JP2020506169 A5 JP 2020506169A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
component
substituted
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019537351A
Other languages
English (en)
Japanese (ja)
Other versions
JP7123058B2 (ja
JP2020506169A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/000109 external-priority patent/WO2018134683A1/en
Publication of JP2020506169A publication Critical patent/JP2020506169A/ja
Publication of JP2020506169A5 publication Critical patent/JP2020506169A5/ja
Priority to JP2022127265A priority Critical patent/JP7481402B2/ja
Application granted granted Critical
Publication of JP7123058B2 publication Critical patent/JP7123058B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019537351A 2017-01-20 2018-01-19 皮膚疾患の処置のための併用療法 Expired - Fee Related JP7123058B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022127265A JP7481402B2 (ja) 2017-01-20 2022-08-09 皮膚疾患の処置のための併用療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762448808P 2017-01-20 2017-01-20
US62/448,808 2017-01-20
PCT/IB2018/000109 WO2018134683A1 (en) 2017-01-20 2018-01-19 Combination therapy for treatment of skin diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022127265A Division JP7481402B2 (ja) 2017-01-20 2022-08-09 皮膚疾患の処置のための併用療法

Publications (3)

Publication Number Publication Date
JP2020506169A JP2020506169A (ja) 2020-02-27
JP2020506169A5 true JP2020506169A5 (cg-RX-API-DMAC7.html) 2021-03-04
JP7123058B2 JP7123058B2 (ja) 2022-08-22

Family

ID=61731720

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019537351A Expired - Fee Related JP7123058B2 (ja) 2017-01-20 2018-01-19 皮膚疾患の処置のための併用療法
JP2022127265A Active JP7481402B2 (ja) 2017-01-20 2022-08-09 皮膚疾患の処置のための併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022127265A Active JP7481402B2 (ja) 2017-01-20 2022-08-09 皮膚疾患の処置のための併用療法

Country Status (8)

Country Link
US (2) US11241467B2 (cg-RX-API-DMAC7.html)
EP (1) EP3570889A1 (cg-RX-API-DMAC7.html)
JP (2) JP7123058B2 (cg-RX-API-DMAC7.html)
CN (2) CN110446505A (cg-RX-API-DMAC7.html)
AU (1) AU2018209393B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019014942A2 (cg-RX-API-DMAC7.html)
CA (1) CA3050208A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018134683A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2021101120A (ru) * 2016-09-15 2022-03-16 Скинтек Лайф Сайенс Лимитед Сублингвальное или буккальное введение dim для лечения заболеваний кожи
BR112019014942A2 (pt) 2017-01-20 2020-04-14 Skintech Life Science Limited terapia de combinação para tratamento de doenças da pele
WO2025097063A1 (en) * 2023-11-01 2025-05-08 Skintech Life Science Limited Topical dim compositions and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665367A (en) * 1996-09-27 1997-09-09 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Skin care compositions containing naringenin and/or quercetin and a retinoid
US6599913B1 (en) * 2001-06-29 2003-07-29 Schering Corporation Treating allergic and inflammatory conditions
US6767563B2 (en) * 2001-10-30 2004-07-27 Michael D. Farley Immune functions
US20030166583A1 (en) * 2002-02-22 2003-09-04 Oliver Yoa-Pu Hu Dermal cytochrome P450 1A inhibitors and enhancers
WO2008057253A2 (en) * 2006-10-27 2008-05-15 Bioresponse, L.L.C. Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles
FR2908604B1 (fr) 2006-11-16 2013-06-28 Physcience Complement alimentaire pour la prevention ou la lutte contre la chute des cheveux, l'acne, l'hirsutisme et la secretion sudorale apocrine excessive.
RU2419426C1 (ru) * 2010-04-26 2011-05-27 Всеволод Иванович Киселев Лекарственное средство на основе дииндолилметана (dim) с повышенной биодоступностью и его использование в лечении гиперпластических и воспалительных заболеваний человека
GB201105050D0 (en) 2011-03-25 2011-05-11 Iiaa Ltd Pharmaceutical agent
SG193926A1 (en) * 2011-04-12 2013-11-29 Nestec Sa Nutritional compositions including branched chain fatty acids and methods of using same
CA2908583A1 (en) * 2013-04-08 2014-10-16 Virginia Commonwealth University Compositions to alleviate presystemic metabolism of opioids
DE102013104441A1 (de) * 2013-04-30 2014-10-16 Bodo C. Melnik Akne-Medikament und Verfahren zu seiner Herstellung
GB2528482A (en) * 2014-07-23 2016-01-27 Skintech Life Science Ltd Pharmaceutical agent
RU2021101120A (ru) * 2016-09-15 2022-03-16 Скинтек Лайф Сайенс Лимитед Сублингвальное или буккальное введение dim для лечения заболеваний кожи
BR112019014942A2 (pt) 2017-01-20 2020-04-14 Skintech Life Science Limited terapia de combinação para tratamento de doenças da pele

Similar Documents

Publication Publication Date Title
JP2023503309A5 (cg-RX-API-DMAC7.html)
JP2007523049A5 (cg-RX-API-DMAC7.html)
RU2011138101A (ru) Фармацевтическая композиция, проявляющая противовоспалительные свойства
CL2011000867A1 (es) Formas cristalinas da, c y ii de (r)-5-[3-cloro-4-(2,3-dihidroxi-propoxi)- benz[z]ilideno]-2- ([z]- propilimino) -3-o- totil-tiazolidin-4-ona; composicion farmaceutica; y uso en el tratamiento o prevencion de rechazo de organos trasplantados, sindrome autoinmunitarios, asma, diabetes, cancer.
NO20075660L (no) Blanding for behandling av inflammatoriske sykdommer
WO2005069933A3 (en) Methods of treating an inflammatory-related disease
JP2006526644A5 (cg-RX-API-DMAC7.html)
IL314009B1 (en) Parp1 inhibitors and uses thereof
JP2014198723A5 (cg-RX-API-DMAC7.html)
MA30344B1 (fr) Pyrazoles actifs sur la 11-beta-hsd-1
WO2015034678A3 (en) Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
AR075179A1 (es) Formulaciones galenicas de compuestos organicos que comprenden alisquireno
JP2019514925A5 (cg-RX-API-DMAC7.html)
WO2022106902A8 (en) Benzenesulfonamide derivatives and uses thereof
FI4101454T3 (fi) Koostumuksia käytettäviksi kohonneen verenpaineen hoitoon
JP2018503685A5 (cg-RX-API-DMAC7.html)
JP2025507472A5 (cg-RX-API-DMAC7.html)
JP2009517411A5 (cg-RX-API-DMAC7.html)
NO20092763L (no) Isosorbid mononitrat derivater for behandling av tarmlidelser
NO20055631L (no) Doseringsform inneholdende pantoprazol som aktiv ingrediens
JP2007119497A5 (cg-RX-API-DMAC7.html)
EA200701923A1 (ru) Лекарственная форма для перорального введения витамина
JP2013032308A5 (cg-RX-API-DMAC7.html)
JP2004521140A5 (cg-RX-API-DMAC7.html)
RU2021101120A (ru) Сублингвальное или буккальное введение dim для лечения заболеваний кожи